z-logo
open-access-imgOpen Access
The PML domain of PML–RARα blocks senescence to promote leukemia
Author(s) -
Katharina Korf,
Harald Wodrich,
Alexander Haschke,
Corinne B. Ocampo,
Lena Harder,
Friederike Gieseke,
Annika Pollmann,
Kevin Dierck,
Sebastian Prall,
Hannah Staege,
Hui Ma,
Martin A. Horstmann,
Ronald M. Evans,
Thomas Sternsdorf
Publication year - 2014
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1412944111
Subject(s) - promyelocytic leukemia protein , death associated protein 6 , fusion protein , acute promyelocytic leukemia , leukemia , biology , cancer research , fusion gene , senescence , retinoic acid , microbiology and biotechnology , nuclear protein , cell culture , gene , immunology , transcription factor , genetics , recombinant dna
Significance Acute promyelocytic leukemia (APL) is a model for oncoprotein-targeted therapy because induced degradation of the promyelocytic leukemia protein–retinoic acid receptor (PML–RAR) fusion protein by retinoic acid and arsenic trioxide essentially eradicates the disease. Here we elucidate a previously unidentified feature of the PML domain, demonstrating that inhibition of cellular senescence may be the key to cell proliferation. We find that PML–RARα acts by blocking the ATRX senescence checkpoint, resulting in its well-known immortalization phenotype. This supports the idea that disruption of the PML-associated ATRX/Daxx–H3.3 chaperone complex is a key feature of PML–RAR fusion, directly linking disruption of cellular senescence to the leukemogenic mechanism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom